AstraZeneca drug Tagrisso gets EU nod for early lung cancer treatment

By Syndicated Content
May 28, 2021 | 2:06 AM
(Reuters) – AstraZeneca’s top-selling Tagrisso drug has been approved for use in the European Union to treat patients with a type of early-stage lung cancer, the company said on Friday.
The European Commission has approved the lung cancer drug as an add-on treatment for adults diagnosed early enough for the tumour to be surgically removed, and who have a mutation of the EGFR gene, the British drugmaker said.
The approval was based on positive results from a late-stage trial called ADAURA, which showed Tagrisso cut the risk of the tumour growing back in patients or death by 80%.

Related Keywords

China ,United States ,Bengaluru ,Karnataka ,India ,United Kingdom ,British ,Roche Tarceva ,Devika Syamnath ,Astrazeneca Iressa ,Vishwadha Chander ,Astrazeneca ,European Union ,European Commission ,Reuters , ,சீனா ,ஒன்றுபட்டது மாநிலங்களில் ,பெங்களூரு ,கர்நாடகா ,இந்தியா ,ஒன்றுபட்டது கிஂக்டம் ,பிரிட்டிஷ் ,ஐரோப்பிய தொழிற்சங்கம் ,ஐரோப்பிய தரகு ,ராய்ட்டர்ஸ் ,